U.S. markets open in 7 hours 37 minutes
  • S&P Futures

    4,165.00
    +9.50 (+0.23%)
     
  • Dow Futures

    34,045.00
    +87.00 (+0.26%)
     
  • Nasdaq Futures

    13,920.75
    +23.50 (+0.17%)
     
  • Russell 2000 Futures

    2,233.80
    +4.50 (+0.20%)
     
  • Crude Oil

    63.95
    +0.57 (+0.90%)
     
  • Gold

    1,769.40
    -1.20 (-0.07%)
     
  • Silver

    25.93
    +0.10 (+0.38%)
     
  • EUR/USD

    1.2064
    +0.0023 (+0.19%)
     
  • 10-Yr Bond

    1.6010
    0.0000 (0.00%)
     
  • Vix

    17.29
    +1.04 (+6.40%)
     
  • GBP/USD

    1.3999
    +0.0015 (+0.10%)
     
  • USD/JPY

    108.2010
    +0.0510 (+0.05%)
     
  • BTC-USD

    54,824.68
    -2,085.26 (-3.66%)
     
  • CMC Crypto 200

    1,234.26
    -64.70 (-4.98%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,074.75
    -610.62 (-2.06%)
     

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors who take an interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) should definitely note that the Independent Chairman, C. Machado, recently paid US$11.52 per share to buy US$115k worth of the stock. That's a very decent purchase to our minds and it grew their holding by a solid 15%.

Check out our latest analysis for Adverum Biotechnologies

Adverum Biotechnologies Insider Transactions Over The Last Year

The President, Leone Patterson, made the biggest insider sale in the last 12 months. That single transaction was for US$325k worth of shares at a price of US$24.68 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$13.42). So it may not tell us anything about how insiders feel about the current share price. The only individual insider seller over the last year was Leone Patterson.

Over the last year, we can see that insiders have bought 43.98k shares worth US$552k. But insiders sold 13.17k shares worth US$325k. In the last twelve months there was more buying than selling by Adverum Biotechnologies insiders. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Adverum Biotechnologies is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Adverum Biotechnologies

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Adverum Biotechnologies insiders own about US$8.7m worth of shares (which is 0.7% of the company). We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At Adverum Biotechnologies Tell Us?

It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Adverum Biotechnologies insiders are expecting a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 4 warning signs for Adverum Biotechnologies (3 make us uncomfortable!) that we believe deserve your full attention.

But note: Adverum Biotechnologies may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.